JP4578581B2 - セロトニン様作用薬としてのインダゾールアミド化合物 - Google Patents

セロトニン様作用薬としてのインダゾールアミド化合物 Download PDF

Info

Publication number
JP4578581B2
JP4578581B2 JP54347598A JP54347598A JP4578581B2 JP 4578581 B2 JP4578581 B2 JP 4578581B2 JP 54347598 A JP54347598 A JP 54347598A JP 54347598 A JP54347598 A JP 54347598A JP 4578581 B2 JP4578581 B2 JP 4578581B2
Authority
JP
Japan
Prior art keywords
compound
formula
pharmaceutically acceptable
acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP54347598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001518906A (ja
JP2001518906A5 (cg-RX-API-DMAC7.html
Inventor
アリシ,アレッサンドラ
ブルファニ,マリオ
カツォッラ,ニコラ
ジャンナンジェリ,マリレナ
ピンツァ,マリオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Publication of JP2001518906A publication Critical patent/JP2001518906A/ja
Publication of JP2001518906A5 publication Critical patent/JP2001518906A5/ja
Application granted granted Critical
Publication of JP4578581B2 publication Critical patent/JP4578581B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Paints Or Removers (AREA)
JP54347598A 1997-04-15 1998-04-02 セロトニン様作用薬としてのインダゾールアミド化合物 Expired - Fee Related JP4578581B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT97A000867 1997-04-15
IT97MI000867A IT1291569B1 (it) 1997-04-15 1997-04-15 Indazolammidi come agenti serotoninergici
PCT/EP1998/002129 WO1998046589A2 (en) 1997-04-15 1998-04-02 Indazole amide compounds as serotoninergic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010100701A Division JP5237324B2 (ja) 1997-04-15 2010-04-26 セロトニン様作用薬としてのインダゾールアミド化合物

Publications (3)

Publication Number Publication Date
JP2001518906A JP2001518906A (ja) 2001-10-16
JP2001518906A5 JP2001518906A5 (cg-RX-API-DMAC7.html) 2005-11-10
JP4578581B2 true JP4578581B2 (ja) 2010-11-10

Family

ID=11376888

Family Applications (2)

Application Number Title Priority Date Filing Date
JP54347598A Expired - Fee Related JP4578581B2 (ja) 1997-04-15 1998-04-02 セロトニン様作用薬としてのインダゾールアミド化合物
JP2010100701A Expired - Fee Related JP5237324B2 (ja) 1997-04-15 2010-04-26 セロトニン様作用薬としてのインダゾールアミド化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010100701A Expired - Fee Related JP5237324B2 (ja) 1997-04-15 2010-04-26 セロトニン様作用薬としてのインダゾールアミド化合物

Country Status (26)

Country Link
US (1) US6197769B1 (cg-RX-API-DMAC7.html)
EP (1) EP0975623B1 (cg-RX-API-DMAC7.html)
JP (2) JP4578581B2 (cg-RX-API-DMAC7.html)
KR (1) KR100563867B1 (cg-RX-API-DMAC7.html)
CN (1) CN1318416C (cg-RX-API-DMAC7.html)
AR (1) AR012426A1 (cg-RX-API-DMAC7.html)
AT (1) ATE219490T1 (cg-RX-API-DMAC7.html)
AU (1) AU740360B2 (cg-RX-API-DMAC7.html)
BG (1) BG64006B1 (cg-RX-API-DMAC7.html)
CA (1) CA2286870C (cg-RX-API-DMAC7.html)
CZ (1) CZ295190B6 (cg-RX-API-DMAC7.html)
DE (1) DE69806141T2 (cg-RX-API-DMAC7.html)
DK (1) DK0975623T3 (cg-RX-API-DMAC7.html)
EA (1) EA002352B1 (cg-RX-API-DMAC7.html)
ES (1) ES2178205T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20022654B (cg-RX-API-DMAC7.html)
HU (1) HU227973B1 (cg-RX-API-DMAC7.html)
IL (1) IL132127A (cg-RX-API-DMAC7.html)
IT (1) IT1291569B1 (cg-RX-API-DMAC7.html)
PL (1) PL193308B1 (cg-RX-API-DMAC7.html)
PT (1) PT975623E (cg-RX-API-DMAC7.html)
SK (1) SK284731B6 (cg-RX-API-DMAC7.html)
TR (1) TR199902546T2 (cg-RX-API-DMAC7.html)
UA (1) UA58550C2 (cg-RX-API-DMAC7.html)
WO (1) WO1998046589A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA982926B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
MXPA03007621A (es) 2001-02-23 2003-12-04 Merck & Co Inc Antagonistas nr2b de n-metil-d-aspartato no arilheterociclicos n-sustituidos.
EP1390034A4 (en) * 2001-04-03 2005-07-13 Merck & Co Inc N-SUBSTITUTED NONARYL HETEROCYCLO AMIDYL-NMDA / NR2B ANTAGONISTS
ITMI20030287A1 (it) 2003-02-18 2004-08-19 Acraf Indazolammidi dotate di attivita' analgesica metodo, per
ITMI20030972A1 (it) 2003-05-15 2004-11-16 Acraf Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende.
ITMI20031468A1 (it) * 2003-07-18 2005-01-19 Acraf Farmaco ativo nel dolore neuropatico
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
DE602005016446D1 (de) * 2004-11-05 2009-10-15 Theravance Inc 5-HT4-Rezeptoragonistenverbindungen
DE602005014566D1 (de) * 2004-11-05 2009-07-02 Theravance Inc Chinolinon-carboxamid-verbindungen
ATE469897T1 (de) * 2004-12-22 2010-06-15 Theravance Inc Indazolcarbonsäureamidverbindungen
US20060183901A1 (en) * 2005-02-17 2006-08-17 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
BRPI0608392A2 (pt) * 2005-03-02 2009-12-29 Theravance Inc compostos de quinolinona como agonistas do receptor 5-ht4
ITMI20062230A1 (it) * 2006-11-22 2008-05-23 Acraf Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende
UA99927C2 (uk) * 2007-11-12 2012-10-25 Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А. Медикамент, який є активним при невропатичному болі
US8377968B2 (en) * 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
CA2833507A1 (en) * 2011-06-07 2012-12-13 Dainippon Sumitomo Pharma Co., Ltd. Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof
WO2013124169A1 (en) * 2012-02-21 2013-08-29 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
EA024939B1 (ru) * 2012-02-21 2016-11-30 Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. 1h-индазол-3-карбоксамидные соединения в качестве ингибиторов гликогенсинтазы киназы 3-бета
WO2014134306A1 (en) 2013-03-01 2014-09-04 Zalicus Pharmaceuticals, Ltd. Heterocyclic inhibitors of the sodium channel
WO2021007487A1 (en) 2019-07-11 2021-01-14 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
NZ243993A (en) * 1991-08-20 1994-10-26 Smithkline Beecham Plc Pharmaceutical compositions having 5-ht4 receptor antagonist activity and selected compounds having such activity
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
WO1996038420A1 (en) * 1995-05-31 1996-12-05 Nisshin Flour Milling Co., Ltd. Indazole derivatives having monocyclic amino group
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici

Also Published As

Publication number Publication date
JP5237324B2 (ja) 2013-07-17
EA199900935A1 (ru) 2000-04-24
HK1027811A1 (en) 2001-01-23
SK284731B6 (sk) 2005-10-06
HUP0002057A2 (hu) 2001-04-28
EP0975623B1 (en) 2002-06-19
WO1998046589A2 (en) 1998-10-22
BG64006B1 (bg) 2003-09-30
KR20010006120A (ko) 2001-01-26
HU227973B1 (hu) 2012-07-30
ITMI970867A1 (it) 1998-10-15
CZ362599A3 (cs) 2000-04-12
DE69806141T2 (de) 2003-01-30
AU740360B2 (en) 2001-11-01
US6197769B1 (en) 2001-03-06
IL132127A (en) 2005-06-19
CA2286870C (en) 2007-05-22
DK0975623T3 (da) 2002-10-14
JP2010195813A (ja) 2010-09-09
EA002352B1 (ru) 2002-04-25
KR100563867B1 (ko) 2006-03-24
IT1291569B1 (it) 1999-01-11
PT975623E (pt) 2002-10-31
AU7215998A (en) 1998-11-11
UA58550C2 (uk) 2003-08-15
SK142399A3 (en) 2000-08-14
EP0975623A2 (en) 2000-02-02
ATE219490T1 (de) 2002-07-15
DE69806141D1 (de) 2002-07-25
PL193308B1 (pl) 2007-01-31
CZ295190B6 (cs) 2005-06-15
WO1998046589A3 (en) 1999-01-28
CN1252798A (zh) 2000-05-10
IL132127A0 (en) 2001-03-19
JP2001518906A (ja) 2001-10-16
GEP20022654B (en) 2002-03-25
ES2178205T3 (es) 2002-12-16
CN1318416C (zh) 2007-05-30
AR012426A1 (es) 2000-10-18
PL336348A1 (en) 2000-06-19
CA2286870A1 (en) 1998-10-22
ZA982926B (en) 1998-10-09
TR199902546T2 (xx) 2000-05-22
HUP0002057A3 (en) 2002-01-28
BG103863A (en) 2000-07-31

Similar Documents

Publication Publication Date Title
JP5237324B2 (ja) セロトニン様作用薬としてのインダゾールアミド化合物
CN101896459B (zh) 驱肠虫药及其用途
AU2003262420B2 (en) Derivatives of N-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics
CZ163276A3 (en) N-(4-piperidinyl)-n-phenyl amides and carbamates
JP2003528046A (ja) フェノキシプロパノールアミン類、それらの製造および治療的使用
AU684874B2 (en) Heterocyclic compounds for the treatment of cns and cardiovascular disorders
CN1178914C (zh) 4-苄基-1-[2-(4-羟基-苯氧基)乙基]-哌啶-3,4-二醇
JP2003517013A (ja) フェノキシプロパノールアミン類、それらの製造方法およびそれらを含む医薬組成物
KR20010053254A (ko) 무스카린성 길항제
EP0558487B1 (en) Piperidine compounds, their preparation and use
EP0937715A1 (en) Tetrahydrobenzindole compounds
IE922090A1 (en) 2-(1-piperidyl)ethanol derivatives, their preparation and¹their therapeutic application
EP1613594B1 (en) 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
HU185432B (en) Process for producing indene derivatives
EP0505465B1 (en) 4-Heterocyclyl-piperidine derivatives, their preparation and their use as inhibitors of calcium overload in brain cells
EP0502031B1 (en) N-substituted azaheterocyclic carboxylic acids and a pharmaceutical composition
HK1027811B (en) Indazole amide compounds as serotoninergic agents
JP2012232980A (ja) 新規製造方法
MXPA99009422A (en) Indazole amide compounds as serotoninergic agents
JPH09291090A (ja) ピペリジノンおよびホモピペリジノン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090304

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090907

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091026

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20091106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100727

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100825

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130903

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees